Back to Trades
Garg Pushkal
EVP Chief R&DCIK 0001829252
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 5
- Buy transactions
- 0
- Sell transactions
- 67
- Companies
- 1
- Active
- 2025–2026
Garg Pushkal, EVP Chief R&D, has filed 5 SEC reports (2025–2026), all concentrated in ALNYLAM PHARMACEUTICALS, INC. (ALNY), totaling $9.8M in disclosed volume. Weighing $0 bought versus $6.4M sold, the history is heavily weighted toward selling. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
5 loaded
| Mar 4 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal | EVP Chief R&D | Sell | $1.1M |
| Feb 17 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal | EVP Chief R&D | Sell | $695.2K |
| Jan 14 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal | EVP Chief R&D | Sell | $547.9K |
| Oct 3 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal | EVP Chief R&D | Sell | $2.7M |
| Aug 19 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal | EVP Chief R&D | Sell | $1.3M |
5 filings